Pierce; Daniel W.

Patent Applications and Registrations

Patent applications and USPTO patent grants for Pierce; Daniel W..The latest application filed is for "antiproliferative compounds and methods of use thereof".

Company Profile

9.9.11

Pierce; Daniel W. - Belmont CA
Pierce; Daniel W. - Hayward CA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Antiproliferative compounds and bispecific antibody against BCMA and CD3 for combined use Grant 11,439,637 - Pierce , et al. September 13, 2	2022-09-13
Antiproliferative Compounds And Methods Of Use Thereof App 20220280505 - Alexander; Matthew D. ; et al.	2022-09-08
Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug Grant 11,320,416 - Peykov , et al. May 3, 2	2022-05-03
Antiproliferative compounds and methods of use thereof Grant 11,185,543 - Alexander , et al. November 30, 2	2021-11-30
Methods For Treating Multiple Myeloma And The Use Of Companion Biomarkers For 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)methy- L)benzyl)piperazin-1-yl)-3-fluorobenzonitrile App 20210181184 - Anton; Maria Soraya Carrancio ; et al.	2021-06-17
Combination Therapy With 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)m- Ethyl)-2,2-difluoroacetamide App 20210128545 - Buchholz; Tonia ; et al.	2021-05-06
Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel Grant 10,900,951 - Peykov , et al. January 26, 2	2021-01-26
Antiproliferative Compounds And Methods Of Use Thereof App 20200253964 - Kind Code	2020-08-13
Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug Grant 10,705,070 - Peykov , et al.	2020-07-07
Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel Grant 10,527,604 - Peykov , et al. J	2020-01-07
Antiproliferative Compounds And Bispecific Antibody Against Bcma And Cd3 For Combined Use App 20190381035 - Pierce; Daniel W. ; et al.	2019-12-19
Methods For Treating Multiple Myeloma And The Use Of Companion Biomarkers For 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoind App 20190361005 - Anton; Maria Soraya Carrancio ; et al.	2019-11-28
Antiproliferative Compounds And Methods Of Use Thereof App 20190282567 - Alexander; Matthew D. ; et al.	2019-09-19
Antiproliferative compounds and methods of use thereof Grant 10,357,489 - Alexander , et al. July 23, 2	2019-07-23
Antiproliferative Compounds And Methods Of Use Thereof App 20190008852 - Alexander; Matthew D. ; et al.	2019-01-10
Method For Treating Cancer Based On Level Of Glucocorticoid Receptor App 20180064679 - PIERCE; Daniel W. ; et al.	2018-03-08
High sensitivity assay for detection of nucleoside diphosphate production Grant 7,824,880 - Baliga , et al. November 2, 2	2010-11-02
High Sensitivity Assay For Detection Of Nucleoside Diphosphate Production App 20090068693 - Baliga; Ramesh ; et al.	2009-03-12
High sensitivity assay for detection of nucleoside diphosphate production Grant 7,416,856 - Baliga , et al. August 26, 2	2008-08-26
High sensitivity assay for detection of nucleoside diphosphate production App 20060257962 - Baliga; Ramesh ; et al.	2006-11-16

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.